This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

This study has been completed.
Information provided by:
Ipsen Identifier:
First received: September 13, 2005
Last updated: May 28, 2009
Last verified: May 2009
The purpose of this study is to determine whether lanreotide 30mg microparticles are effective in the relief of clinical symptoms due to small bowel obstruction in inoperable patients with peritoneal carcinomatosis.

Condition Intervention Phase
Intestinal Obstruction Carcinoma Peritoneal Neoplasms Drug: Lanreotide (microparticle formulation) Other: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients.

Resource links provided by NLM:

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Percentage of responder patients (patient with 1 or less vomiting episode per day during at least 3 consecutive days or in whom nasogastric tube (NGT) has been removed during at least three consecutive days without vomiting recurrence) [ Time Frame: On day 7 (plus 1 day at the latest) after the first injection ]

Secondary Outcome Measures:
  • Number of daily vomiting episodes or measurement of the daily drainage by NGT [ Time Frame: Daily for the duration of the study ]
  • Number of days with no vomiting episodes [ Time Frame: For the duration of the study ]
  • Number of daily nausea episodes [ Time Frame: Daily for the duration of the study ]
  • Intensity of abdominal pain [ Time Frame: Daily for the duration of the study ]
  • Well-being [ Time Frame: Daily for the duration of the study ]
  • Symptom relief duration [ Time Frame: Between the first day of clinical response and the end of follow-up ]

Enrollment: 80
Study Start Date: September 2003
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Lanreotide (microparticle formulation)
A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
Placebo Comparator: 2 Other: Placebo
A single intra-muscular injection on day 0.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • digestive obstruction located in the upper part of the gastro-intestinal tract
  • digestive obstruction of malignant origin
  • peritoneal carcinomatosis confirmed by a CT Scan
  • at least two vomiting episodes per day or a presence of a nasogastric suction tube
  • inoperable patients

Exclusion Criteria:

  • specific anticancer therapy within the previous 15 days
  • signs of bowel perforation
  • somatostatin or any analogue as treatment of the bowel obstruction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00216372

  Show 53 Study Locations
Sponsors and Collaborators
Study Director: Sandrine Lewin Ipsen
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Sandrine Lewin, Ipsen Identifier: NCT00216372     History of Changes
Other Study ID Numbers: 2-54-52030-156 (408)
Study First Received: September 13, 2005
Last Updated: May 28, 2009

Keywords provided by Ipsen:

Additional relevant MeSH terms:
Peritoneal Neoplasms
Intestinal Obstruction
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Abdominal Neoplasms
Neoplasms by Site
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Antineoplastic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 19, 2017